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Abstract: Background: Anti-cytomegalovirus hyperimmunoglobulin (CMVIg) was shown to 
provide beneficial immunodulatory properties beyond antiviral efficacies. The aim of this 
retrospective study was to assess the impact of prophylactic CMVIg treatment on early outcome 
following liver transplantation (LT) in critically ill patients. Methods: Forty-three cirrhotic patients 
requiring pre-LT intensive care due to multiorgan failure were analyzed. Twenty-eight patients 
with enhanced CMV risk (D+/R+; D+/R−; D−/R+) received prophylactic CMVIg for a minimum of 7 
days, while 15 patients (D−/R−) did not. Results: Post-transplantation rates of intra-abdominal 
infections (28% vs. 61.1%; p = 0.03), Epstein–Barr virus infections (0% vs. 33.3%; p = 0.034), allograft 
rejections (0% vs. 22.2%; p = 0.013) and sepsis-related mortality (4% vs. 27.8%; p = 0.026) were 
significantly lower, whereas incidence of CMV infections (4% vs. 22.2%; p = 0.066) tended to be lower 
in the CMVIg subset. In multivariate analysis, only pretransplant elevated serum lactate level 
(hazard ratio = 34.63; p = 0.009) and absence of CMVIg therapy (hazard ratio = 21.76; p = 0.023) were 
identified as independent promoters of 3-month mortality. Conclusion: Prophylactic treatment with 
CMVIg reduces predisposition for severe immunological and septic events and, thereby, early 
mortality in critically ill liver recipients. 
Keywords: liver transplantation; critical illness; multiorgan failure; CMV infection; anti-CMV 
hyperimmunoglobulin; immune modulation 
 
1. Introduction 
The implementation of the “sickest first” allocation policy using the so-called Model of End-
Stage Liver Disease (MELD) score almost 2 decades ago has clearly proven effective in reducing 
waiting list mortality in many large liver transplantation (LT) programs around the world [1]. Due 
to a growing disparity between demand and availability of appropriate donor organs, pre-LT waiting 
times and final MELD scores have been, however, significantly increasing in recent years; 
consequently, transplant patients have become sicker and more complex [1,2]. In particular, 
multiorgan failure (MOF) requiring intensive care unit (ICU) support, as is common in patients with 
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acute-on-chronic liver failure (ACLF), was shown to be a major risk factor of early morbidity and 
mortality following LT [3–5]. Considering other established transplant indications that are associated 
with a much better prognosis, LT in ICU-bound patients not only represents a medical challenge but 
also raises important ethical issues [6]. In order to avoid futility in patients being “too sick” for 
transplant, a profound interdisciplinary risk assessment using reliable prognostic factors is 
mandatory [7]. Nonetheless, owing to an enhanced susceptibility to severe immunological and septic 
complications, the postoperative course in this specific LT-subset remains highly demanding [3–5], 
thus requiring the implementation of effective immunoprotective concepts beyond adjustment of 
immunosuppressive treatment [8,9]. 
In this context, prevention of early cytomegalovirus (CMV) infection seems to be of particular 
prognostic importance, since besides causing direct organ damages, it may indirectly affect outcome 
by modulating the recipients’ immune response. Triggered by proinflammatory cytokine release and 
various immunosuppressive mechanisms, an immunological risk may, thereby, be aggravated [10]. 
Although antiviral prophylaxis by ganciclovir or valganciclovir is nowadays widely established in 
patients with high-risk CMV immunoglobulin (Ig) G donor (D)/recipient (R) seroconstellation 
(D+/R−), this is usually not applicable in severely immunocompromised allograft recipients due to 
intolerance against common side effects like renal dysfunction, leukopenia and thrombocytopenia 
[11]. That is why anti-CMV hyperimmunoglobulin (CMVIg) for passive immunization is meanwhile 
increasingly reconsidered in selected patients [12]. Although tolerability and antiviral efficacies of 
CMVIg have clearly been confirmed in the past [13], its use is currently not a recommended standard 
for antiviral prophylaxis or treatment in the LT setting [14]. In recent years, there seems to be growing 
suggestive evidence that, apart from antiviral activities, CMVIg may provide anti-inflammatory and 
immunoregulatory properties that could be valuable to counteract CMV-related immune reactions 
[12,15–17]. We hypothesized that critically ill liver recipients, who are particularly threatened by early 
inflammatory events, might benefit from these positive immunomodulatory capabilities. The aim of 
the presented retrospective study was to assess the prognostic impact of prophylactic CMVIg therapy 
on early outcome in a series of highest acuity ICU-bound LT patients. 
2. Material and Methods 
2.1. Study Cohort 
From a prospectively managed LT database, 43 adult cirrhotic patients with hepatic 
decompensation requiring ICU support prior to LT were identified between 2007 and 2012. At the 
time of listing, all of them had expressed their consent that data may be used for scientific purpose. 
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was 
approved by the institutional review board of the Medical School of the Technical University of 
Munich (No. 217/15). It is noteworthy that no organs from executed donors were used in this 
investigation. Progressive liver cirrhosis was assessed by clinical and radiographic criteria prior to 
registration and could be confirmed on histopathological analysis of the explanted livers. Patients 
with acute liver failure were not included in the study. In addition to liver dysfunction, all patients 
suffered from associated neurologic, hemodynamic, respiratory or renal failure requiring mechanical 
invasive ventilation, continuous vasopressor administration or renal replacement therapy. “Fatal 
triad” indicated the necessity of pulmonary, circulatory and renal support. Laboratory (lab.) MELD 
scores at listing and at LT were used for describing MELD dynamics (ΔMELD score = (lab.) MELD 
score at registration – (lab.) MELD score at LT). Diagnosis and grading (grades 1–3) of ACLF and 
related MOF were based on the European Association for the Study of the Liver—Chronic Liver 
Failure (EASL-CLIF) Consortium consensus criteria. The respective CLIF-C organ failure (OF) score 
(range: 11–18) at LT was calculated for each patient [18]. Preoperative serum lactate levels (normal 
range: <1.8 mmol/L) were used for describing severity of critical illness and tissue hypoxia [19,20], 
whereas values of C-reactive protein (CRP; normal range: <0.5 mg/dL), interleukin-6 (IL-6; normal 
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range: <7 pg/mL) and procalcitonin (PCT; normal range: <0.1 ng/mL) reflected extent of systemic 
inflammatory response reaction prior to LT [21]. 
2.2. Donor Factors 
The following prognostically relevant donor factors were included in risk analysis: age, body 
mass index, donor risk index, liver allograft reperfusion performance, cold and warm ischemia times. 
2.3. Treatment with CMVIg and Post-Transplant Follow-Up 
According to our standard transplant protocol, ICU-bound liver recipients with an increased 
CMV risk (D+/R+; D+/R−; D−/R+) received prophylactic intravenous CMVIg (Cytotect™, Biotest, 
Dreieich, Germany) with a dose of 100 IE (Ehrlich)/kg/day (≙ 1mL/kg/day; infusion rate: 0.8 
mL/kg/h), starting at the first post-LT day and continued for a minimum of 1 week, whereas D−/R− 
patients were not treated. As a result of MOF, none of the study patients were eligible for specific 
antiviral medication. Serum DNA loads of CMV and Epstein–Barr virus (EBV) were determined in 
all patients twice a week during post-LT ICU stay and weekly at minimum thereafter for the first 3 
months by real-time PCR (ThermoFisher 7500 Real-Time PCR System, ThermoFisher Scientific Inc., 
USA). Detectable CMV DNAemia at any level indicated CMV infection. Immunosuppressive therapy 
consisted of a dual regimen by tacrolimus (Tac; intended trough level: 5–7 ng/dL) and corticosteroids. 
Biopsy-proven allograft rejection was treated with methylprednisolone bolus/Tac-dose adjustment. 
Peak serum levels of CRP, IL-6 and PCT during 1 month post-LT described early systemic state of 
inflammation [21]. 
2.4. Statistical Analysis 
Quantitative variables were expressed in median and range and compared by ANOVA analysis. 
Qualitative variables were reported in frequencies and percentages and compared by chi-squared 
test. Post-LT survival rates were determined by Kaplan–Meier method and compared using log rank 
test. Factors of early (3-month) mortality were assessed by uni- and multivariate logistic regression 
analysis. A p < 0.05 was considered statistically significant. All statistical analyses were performed 
using SPSS 24.0 software (IBM Inc., Munich, Germany). 
3. Results 
3.1. Patients’ Characteristics 
Median age of the study population was 58 years (range: 32–68), with ethyltoxic liver disease 
(58.1%) and viral hepatitis (23.3%) being the major transplant indications. Median (lab.) MELD scores 
at listing and at LT were 28 (range: 7–40) and 38 (range: 30–40), respectively, resulting in a median 
ΔMELD of 9 (range: 0–32). Pre-LT waiting times measured from registration and from final hospital 
admittance ranged between 4 days and 36 months (median: 3 months) and between 3 and 71 days 
(median: 15 days), respectively. All patients were ICU-bound prior to LT for a median of 6 days 
(range: 2–42). With regard to ACLF, patients were classified grade 1 in 2 (4.7%), grade 2 in 10 (23.3%), 
and grade 3 in 31 cases (72.1%). Twenty-five patients required dialysis (58.1%), 36 patients received 
vasopressors (83.7%), and 18 patients (41.9%) were on ventilation treatment prior to LT. Twenty-five 
liver recipients (58.1%) received prophylactic anti-CMV Ig for a median of 7 days (range: 7–20; Table 
1). Recipients’ age was significantly lower and pre-LT CRP and IL-6 levels tended to be lower in the 
CMVIg subset, whereas in contrast, no significant differences were noticed regarding severity of liver 
disease and MOF. In addition, donor variables were comparable between both subsets (Table 1). 
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Table 1. Pretransplant patients’ and donors’ characteristics. 
Patients’ Characteristics Non-CMVIg (n = 18) CMVIg (n = 25) p Value 
Age 62 (39–68) 56 (32–67) 0.007 
Male sex 12 (66.7%) 16 (64%) 0.856 
Genesis of Cirrhosis 
Ethyltoxic 12 (66,6%) 13 (52%) 
0.519 
Viral hepatitis 4 (22.2%) 6 (24%) 
Autoimmune 1 (5.6%) 5 (20%) 
Cryptogenic 1 (5.6%) 0 (0%) 
Other 0 (0%) 1 (4%) 
CMV Seroconstellation 
D−/R− 18 (100%) 0 (0%) 
<0.001 D−/R+ 0 (0%) 7 (28%) 
D+/R− 0 (0%) 14 (56%) 
D+/R+ 0 (0%) 4 (16%) 
Serum bilirubin level in mg/dL at LT 14 (4.8–31.9) 14 (6.9–58) 0.232 
Serum creatinine level in mg/dL at LT 2.6 (0.5–3.8) 2.5 (1.4–5.5) 0.579 
International normalized ratio at LT 2.3 (1.5–3.1) 2.5 (1.2–4.0) 0.186 
Serum natrium level in mmol/L at LT 130 (125–145) 133 (119–147) 0.523 
(lab.) MELD score at listing 25.5 (12–40) 30 (7–40) 0.486 
(lab.) MELD score at LT 39 (31–40) 38 (30–40) 0.621 
ΔMELD score 10 (0–28) 9 (0–32) 0.752 
Waiting time from registration in months 3 (0.5–25) 3 (0.1–36) 0.642 
Waiting time from final admittance in days 14.5 (3–41) 17 (3–71) 0.225 
Ascites at LT 18 (100%) 23 (92%) 0.219 
Bacterial infection at LT 10 (55.6%) 10 (40%) 0.313 
Duration of pre-LT ICU stay in days 7.5 (0–35) 4 (0–42) 0.276 
Ventilation at LT 9 (50%) 8 (32%) 0.234 
Vasopressors at LT 15 (83.3%) 21 (84%) 0.953 
Renal replacement therapy at LT 10 (55.5%) 15 (60%) 0.771 
Fatal triad at LT 6 (33.3%) 6 (24%) 0.501 
Acute on Chronic Liver Failure at LT 
Grade 1 0 (0%) 2 (8%) 
0.452 Grade 2 5 (27.8%) 5 (20%) 
Grade 3 13 (72.2%) 18 (72%) 
Organ Failures (According CLIF-C) at LT 
Liver 11 (61.1%) 13 (52%) 0.553 
Kidney 18 (100%) 23 (92%) 0.219 
Circulation 15 (83.3%) 21 (84%) 0.935 
Respiration 10 (55.6%) 9 (36%) 0.201 
Coagulation 10 (55.6%) 14 (56%) 0.977 
Neurology 9 (50%) 9 (36%) 0.359 
Number of Organ Failures at LT 
≤ 3 7 (38.9%) 13 (52%) 
0.395 
> 3 11 (61.1%) 12 (48%) 
CLIF-C OF score at LT 16 (11–18) 15 (11–18) 0.460 
Lactate level in mmol/L at LT 3.0 (0.9–10) 3 (0.9–5.8) 0.373 
CRP level in mg/dL at LT 3.8 (0.7–6.1) 3 (0.4–7.2) 0.058 
PCT level in ng/mL at LT 2.5 (0.4–7) 1.3 (0.3–49.9) 0.480 
IL-6 level in pg/mL at LT 22 (6–78) 17 (5–45) 0.074 
Donor Variables 
Age 54 (18–75) 57 (29–71) 0.428 
Body mass index 1.8 (1.1–2.5) 1.9 (1.3–2.3) 0.399 
Donor risk index 26 (22–32) 26 (19–40) 0.881 
Allograft Reperfusion Performance 
Well 5 (27.8%) 10 (40%) 
0.342 
Acceptable 8 (44.4%) 10 (40%) 
Moderate 5 (27.8%) 3 (12%) 
Poor 0 (0%) 2 (8%) 
Cold ischemia time in min 545 (350–1140) 600 (360–900) 0.857 
Warm ischemia time in min 51 (30–68) 45 (20–90) 0.596 
CMVIg, anti-CMV hyperimmunoglobulin; LT, liver transplantation; CMV, cytomegalovirus; MELD, 
model of end-stage liver disease; ICU, intensive care unit; ACLF, acute-on-chronic liver failure; CLIF-
C, chronic liver failure consortium; OF, organ failure; CRP, C-reactive protein; PCT, procalcitonin; IL-
6, interleukin-6. 
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3.2. Early Post-LT Outcome 
Treatment was well-tolerated in all cases, without need of dose reduction. Median total number 
of CMVIg doses/patient was 7 (range: 7–20). The incidence of intra-abdominal infections was 
significantly higher in the non-CMVIg cohort, while rates of systemic bacterial infections were 
comparable (Table 2). One patient of the CMVIg- (4%) but four of the non-CMVIg subset (22.2%) 
developed CMV infection. Apart from that, incidence of EBV infections was significantly higher 
without therapy. Allograft rejection rates were 0% for the CMVIg cohort and 22.2% for the non-
CMVIg cohort (Table 2). Post-transplant peak serum levels of CRP, IL-6 and PCT were all 
significantly lower following anti-CMV Ig treatment, whereas Tac levels were comparable (Figure 1). 
Table 2. Post-LT outcome at 3 months. 
 Non-CMVIg (n = 18) CMVIg (n = 25) p Value 
Systemic bacterial infection 7 (38.9%) 9 (36%) 0.847 
Intra-abdominal bacterial infection 11 (61.1%) 7 (28%) 0.030 
CMV infection 4 (22.2%) 1 (4%) 0.066 
EBV infection 3 (33.3%) 0 (0%) 0.034 
Biopsy proven allograft rejection 4 (22.2%) 0 (0%) 0.005 
Mortality 7 (38.9%) 2 (8%) 0.014 
Death by septic MOF 5 (27.8%) 1 (4%) 0.026 
CMVIg, anti-CMV hyperimmunoglobulin; CMV, cytomegalovirus; EBV, Epstein–Barr virus; MOF, 
multiorgan failure. 
 
Figure 1. Post-LT peak serum levels of CRP (A), p < 0.001; IL-6 (B), p < 0.001 and PCT (C) p = 0.017 
were all significantly lower following CMVIg treatment, whereas peak Tac levels (D) p = 0.336 were 
comparable. 
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3.3. Prognostic Factors of 3-Month Mortality 
At 3 months post-LT, nine liver recipients had died (20.9%), two in the CMVIg (8%) subgroup 
and seven in the non-CMVIg subgroup (38.9%). Corresponding mortality rates due to septic MOF 
were 4% and 27.8%, respectively (Table 2). In univariate analysis, MELD score at listing, ΔMELD, 
ICU stay, fatal triad, CMVIg treatment, cold ischemia time and serum levels of lactate, CRP and IL-6 
exerted a prognostic impact (Table 3). Only pre-LT elevated lactate level and absence of CMVIg 
therapy were identified as independent promoters of 3-month mortality, whereas cold ischemia time 
almost reached statistical significance (Table 4). Respective survival curves are illustrated in Figure 
2. 
Table 3. Univariate prognostic factors of 3-month mortality. 
Variables 
Alive at 3 Months 
(n = 34) 
Dead at 3 Months 
(n = 9) 
p Value 
Recipients‘ Age 58 (32–68) 61 (39–67) 0.278 
Male sex 21 (61.7%) 7 (77.8%) 0.370 
MELD at listing 30 (7–40) 15 (12–40) 0.019 
MELD at LT 38 (30–40) 40 (31–40) 0.582 
Δ MELD 9 (0–32) 16 (0–28) 0.047 
Waiting time from registration in months 2.25 (0.1–36) 6 (1.5–25) 0.134 
Waiting time from final admittance in days 13.5 (3–71) 26 (3–43) 0.229 
Duration of pre-LT ICU stay in days 5 (2–16) 10 (2–42) 0.002 
Ascites at LT 32 (94.1%) 9 (100%) 0.456 
Bacterial infection at LT 15 (44.1%) 5 (55.6%) 0.541 
Grade of ACLF (3 vs. 1 or 2) at LT 26 (76.5%) 5 (55.6%) 0.214 
Number of pre-LT organ failures according 
CLIF-C 4 (1–6) 5 (2–6) 0.579 
CLIF-C OF score at LT 15.5 (11–18) 16 (11–18) 0.935 
Ventilation at LT 13 (38.2%) 5 (55.6%) 0.349 
Vasopressors at LT 29 (85.3%) 7 (77.8%) 0.587 
Renal replacement therapy at LT 18 (52.9%) 7 (77.8%) 0.179 
Fatal triad at LT 7 (20.6%) 5 (55.6%) 0.038 
Lactate level in mmol/L at LT 3 (0.9–5.6) 4.9 (1.9–10) <0.001 
CRP level in mg/dL at LT 3 (0.4–6) 5.6 (0.8–7.2) 0.013 
PCT level in ng/mL at LT 1.5 (0.3–49.9) 3.6 (2–35.5) 0.264 
IL-6 level in pg/mL at LT 19 (5–45) 25 (6–78) 0.003 
Peak Tac level in ng/dL 10 (7–23.5) 14 (7–20) 0.169 
Lack of CMVIg treatment 11 (32.4%) 7 (77.8%) 0.014 
Donors’ Age 57 (18–75) 46 (27–71) 0.172 
Donor body mass index 1.9 (1.07–2.50) 1.62 (1.08–2.15) 0.082 
Donor risk index 26 (19–40) 25 (22–32) 0.447 
Moderate/poor allograft reperfusion 10 (29.4%) 0 (0%) 0.063 
Cold ischemia time in min 585 (350–900) 720 (450–1140) 0.009 
Warm ischemia time in min 51.5 (20–70) 40 (300–90) 0.681 
MELD, model of end-stage liver disease; LT, liver transplantation; ICU, intensive care unit; ACLF, 
acute-on-chronic liver failure; CLIF-C, chronic liver failure consortium; OF, organ failure; CRP, C-
reactive protein; PCT, procalcitonin; IL-6, interleukin-6; CMVIg, anti-CMV hyperimmunoglobulin. 
Table 4. Multivariate prognostic factors of 3-month mortality. 
Variables HR CI 95% p Value 
Lactate level (> vs. ≤3 mmol/L) 34.63 2.383–503.198 0.009 
CMVIg treatment (no vs. yes) 21.76 1.540–307.368 0.023 
Cold ischemia time (> vs. ≤600 min) 11.49 0.966–136.786 0.053 
HR, hazard ratio; CI, confidence interval; CMVIg, anti-CMV hyperimmunoglobulin. 
  




Figure 2. (A) Postoperative survival rates at 3 months were 92.9% and 53.3% in patients with pre-LT 
serum lactate levels ≤ versus >3 mmol/L, respectively, log rank = 0.002. (B) Survival rates in patients 
receiving and those not receiving CMVIg were 92% and 61.1%, respectively, log rank = 0.02. 
4. Discussion 
The results of our study indicate that prophylactic administration of CMVIg reduces early 
morbidity and mortality following LT in critically ill cirrhotic patients, most probably related to 
positive immune modulation with regard to CMV risk, allograft immunogenicity and predisposition 
for septic events (Table 2). 
Owing to evidenced antiviral efficacies and low adverse-effect profile, anti-CMV Ig has for a 
long time been the cornerstone in prophylaxis and treatment of CMV infection following solid organ 
transplantation. However, in the context of potent and cheaper antiviral drugs that have been 
implemented in the last years [11], it has clearly lost significance. Recent guidelines issued by the 
Transplantation Society do not generally recommend prophylaxis with CMVIg, but rather suggest 
augmentation of antiviral medication in high-risk organ recipients, who require intensified 
immunosuppression, such as patients following thoracic and intestinal transplantation. Apart from 
that, its administration may be considered on an individual basis as rescue treatment in severe CMV 
diseases or ganciclovir-resistant courses [14]. 
Currently, there is growing experimental and clinical evidence that, independent from 
established antiviral capacities, CMVIg provides immunological benefits that seem to be rather 
comparable to those of polyvalent Ig preparations [12,15,16]. Even though the complex mechanisms 
of immune modulation are not yet fully understood, it appears to affect several aspects of the innate 
and adaptive immune response, resulting in a combination of immunosuppressive (inhibition of 
dendritic maturation and suppression of T cells), immunostimulatory (passive anti-CMV 
immunization and increasing levels of naïve B cells) and anti-inflammatory (decreasing production 
of IL-2, interferon-y and IL-10) efficacies [12,15–17,22–24]. In fact, lower incidences of immunological 
and infectious complications following anti-CMV Ig therapy have been demonstrated in some recent 
studies on adult and pediatric LT [25–28]. In the largest investigation thus far on this topic presented 
several years ago, Fischer et al. reported on reduced risk of allograft loss and death in 2350 liver 
recipients receiving CMVIg, without, however, stratifying data on extent of liver decompensation 
and MOF [28]. 
To the best of our knowledge, we here present the first study analyzing the impact of 
prophylactic CMVIg in severely ill ICU-bound liver transplant patients. Apart from pre-LT serum 
lactate, which is an established prognostic factor in this clinical setting [19,20], only lack of anti-CMV 
Ig therapy was identified as an independent promoter of early mortality in our series (Table 4). 
A B 
J. Clin. Med. 2020, 9, 656 8 of 10 
 
 
According to our findings, different immunomodulatory aspects may be discussed as possible 
triggers for the observed prognosis improvement. 
First, despite higher serological CMV risk, we noticed a clear trend of lower CMV incidence in 
the CMVIg subset (4% vs. 22.2%), which in view of well-known direct and indirect CMV-related 
harms could have been involved in superior outcome. Thus, our data emphasize on the prognostic 
importance of implementing passive CMV-specific immunity in those cases where recommended 
antiviral prophylaxis is not feasible [17]. Second, rates of acute allograft rejections (0% vs. 27.8%) and 
severe septic events (4% vs. 27.8%) were both significantly lower in our treatment group (Table 2), 
even though contradictory trends are frequently observed in clinical reality. Therefore, anti-CMV Ig 
appears to stabilize the immunological balance between allograft immunogenicity on the one hand 
and susceptibility for infections on the other, which may be fundamental for reducing early morbidity 
and mortality in immunocompromised liver recipients [29]. In this context, a higher rate of EBV 
reactivation (33% vs. 0%; Table 2) may be regarded as another indicator of immunological dysbalance 
in the non-CMVIg subgroup [30]. Third, significantly lower post-LT peak serum levels of 
proinflammatory mediators (Figure 1) suggested a beneficial impact on early systemic 
immunological response reaction [21]. 
Retrospective design and low sample size are limitations of our study and may well explain the 
high 95% confidence interval in our multivariate analysis (Table 4). Apart from that, the prognostic 
value of CMVIg in low risk patients (D−/R−) remained undefined. Also, nonconsidered differences 
in proinflammatory activation might have biased our results. In fact, the immunological performance 
may be influenced by (pre-LT) background inflammation, donor liver function and (post-LT) 
immunosuppressive treatment [30]. Apart from recipients’ age, which in turn may have had a 
prognostic impact in our analysis [3–5], we did not find significant differences in patients’ 
characteristics, donor features and immunosuppressive levels (Table 1). However, dynamic immune 
monitoring including repeat IgG level determinations and immunosuppressive drug exposure 
studies are required for a more precise immunological assessment. Finally, we cannot exclude that 
treatment with nonspecific Ig might have provided similar immunomodulatory efficacies than 
CMVIg. Recently, a beneficial efficacy of IgM-enriched Ig on hemodynamic stability and 30-day 
mortality was reported in a series of 21 patients suffering from post-LT vasoplegia requiring 
vasopressor treatment. However, there was no control group and, moreover, the study was lacking 
data on pre-LT status and CMV-specific outcome [31]. Thus, in our opinion, the combination of both 
anti-CMV impact and immunoregulatory properties renders CMVIg more attractive for critically ill 
liver recipients than conventional Ig preparations, which do not specifically inhibit viral activities. 
However, a comparative investigation is needed to further elucidate this issue. 
Particular strengths of our investigation included a comprehensive generation of preoperative 
background and post-LT follow-up data and, above all, topicality of the subject and novelty of our 
findings. Although the “sickest first” policy has clearly defined and transparent rules and regulations 
[32], decision-making process in times of a dramatic donor shortage is determined not only by 
considerations of medical feasibility, but also, to a large extent, by ethical concerns. Individual 
urgency and possible benefit in highly complex LT candidates have to be weighed against common 
utility [6], which is hampered by lack of well-defined drop-out criteria and, besides, by an enormous 
pressure to succeed with regard to survival rates and profitability of the program [6,7]. Instead of 
defining transplant futility [7,20,33], we were rather focusing on immunological aspects to improve 
survival of highest acuity LT patients who most probably had been rejected at utility-guided centers. 
Against this background, our reported 3-month survival rate of 92% following anti-CMV Ig treatment 
represents an extraordinary outcome result, especially when considering that death would have been 
the most likely alternative. 
5. Conclusions 
In summary, our study suggests that critically ill liver recipients benefit from prophylactic 
CMVIg treatment by an improved risk profile for immunological and infectious complications and, 
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thereby, from reduced early mortality. However, this needs to be validated in a prospective 
multicenter study approach, including immunological analyses for clarifying the underlying 
immunomodulatory mechanisms of action. 
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